CRISPR-cas technology: emerging applications in clinical microbiology and infectious diseases

Sahar Serajian; Ehsan Ahmadpour; Sonia M. Rodrigues Oliveira; Maria de Lourdes Pereira; Siamak Heidarzadeh

doi:10.3390/ph14111171

CRISPR-cas technology: emerging applications in clinical microbiology and infectious diseases

Sahar Serajian, Ehsan Ahmadpour, Sonia M. Rodrigues Oliveira, Maria de Lourdes Pereira, Siamak Heidarzadeh

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Through the years, many promising tools for gene editing have been developed including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR-associated protein 9 (Cas9), and homing endonucleases (HEs). These novel technologies are now leading new scientific advancements and practical applications at an inimitable speed. While most work has been performed in eukaryotes, CRISPR systems also enable tools to understand and engineer bacteria. The increase in the number of multi-drug resistant strains highlights a necessity for more innovative approaches to the diagnosis and treatment of infections. CRISPR has given scientists a glimmer of hope in this area that can provide a novel tool to fight against antimicrobial resistance. This system can provide useful information about the functions of genes and aid us to find potential targets for antimicrobials. This paper discusses the emerging use of CRISPR-Cas systems in the fields of clinical microbiology and infectious diseases with a particular emphasis on future prospects.

Original language	English
Article number	1171
Number of pages	23
Journal	Pharmaceuticals
Volume	14
Issue number	11
DOIs	https://doi.org/10.3390/ph14111171
Publication status	Published - Nov 2021
Externally published	Yes

Keywords

CRISPR
Gene editing
Infectious diseases
Antimicrobial resistance
Parasitology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ph14111171Licence: CC BY

Cite this

@article{3e8adbb4471f4651a1410f8e82536bcb,

title = "CRISPR-cas technology: emerging applications in clinical microbiology and infectious diseases",

abstract = "Through the years, many promising tools for gene editing have been developed including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR-associated protein 9 (Cas9), and homing endonucleases (HEs). These novel technologies are now leading new scientific advancements and practical applications at an inimitable speed. While most work has been performed in eukaryotes, CRISPR systems also enable tools to understand and engineer bacteria. The increase in the number of multi-drug resistant strains highlights a necessity for more innovative approaches to the diagnosis and treatment of infections. CRISPR has given scientists a glimmer of hope in this area that can provide a novel tool to fight against antimicrobial resistance. This system can provide useful information about the functions of genes and aid us to find potential targets for antimicrobials. This paper discusses the emerging use of CRISPR-Cas systems in the fields of clinical microbiology and infectious diseases with a particular emphasis on future prospects. ",

keywords = "CRISPR, Gene editing, Infectious diseases, Antimicrobial resistance, Parasitology",

author = "Sahar Serajian and Ehsan Ahmadpour and Oliveira, {Sonia M. Rodrigues} and Pereira, {Maria de Lourdes} and Siamak Heidarzadeh",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = nov,

doi = "10.3390/ph14111171",

language = "English",

volume = "14",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "MDPI",

number = "11",

}

TY - JOUR

T1 - CRISPR-cas technology

T2 - emerging applications in clinical microbiology and infectious diseases

AU - Serajian, Sahar

AU - Ahmadpour, Ehsan

AU - Oliveira, Sonia M. Rodrigues

AU - Pereira, Maria de Lourdes

AU - Heidarzadeh, Siamak

PY - 2021/11

Y1 - 2021/11

N2 - Through the years, many promising tools for gene editing have been developed including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR-associated protein 9 (Cas9), and homing endonucleases (HEs). These novel technologies are now leading new scientific advancements and practical applications at an inimitable speed. While most work has been performed in eukaryotes, CRISPR systems also enable tools to understand and engineer bacteria. The increase in the number of multi-drug resistant strains highlights a necessity for more innovative approaches to the diagnosis and treatment of infections. CRISPR has given scientists a glimmer of hope in this area that can provide a novel tool to fight against antimicrobial resistance. This system can provide useful information about the functions of genes and aid us to find potential targets for antimicrobials. This paper discusses the emerging use of CRISPR-Cas systems in the fields of clinical microbiology and infectious diseases with a particular emphasis on future prospects.

AB - Through the years, many promising tools for gene editing have been developed including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR-associated protein 9 (Cas9), and homing endonucleases (HEs). These novel technologies are now leading new scientific advancements and practical applications at an inimitable speed. While most work has been performed in eukaryotes, CRISPR systems also enable tools to understand and engineer bacteria. The increase in the number of multi-drug resistant strains highlights a necessity for more innovative approaches to the diagnosis and treatment of infections. CRISPR has given scientists a glimmer of hope in this area that can provide a novel tool to fight against antimicrobial resistance. This system can provide useful information about the functions of genes and aid us to find potential targets for antimicrobials. This paper discusses the emerging use of CRISPR-Cas systems in the fields of clinical microbiology and infectious diseases with a particular emphasis on future prospects.

KW - CRISPR

KW - Gene editing

KW - Infectious diseases

KW - Antimicrobial resistance

KW - Parasitology

UR - http://www.scopus.com/inward/record.url?scp=85119851378&partnerID=8YFLogxK

U2 - 10.3390/ph14111171

DO - 10.3390/ph14111171

M3 - Article

C2 - 34832953

SN - 1424-8247

VL - 14

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 11

M1 - 1171

ER -

CRISPR-cas technology: emerging applications in clinical microbiology and infectious diseases

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this